The faster p‐tau217 increase in APOE ɛ4 carriers is in accordance with the accelerated cognitive decline of APOE ɛ4 carriers, supporting the notion that p‐tau217 is superior to the other p‐tau analytes to measure disease progression.44 Here, MAPT is linked to Mental deterioration.